This report from Life Science Intelligence provides the latest market data for the Global Oncology Ablation Catheters Market. Information covered by this report includes:
· unit volumes & pricing forecast from 2019-2024
· analyses of the leading companies, and
· global market share analysis.
The global market for oncology ablation catheters was valued at an estimated $59.2 million in 2020 and is projected to increase at a CAGR (2020-2024) of 6.7%. Product segments covered by this report include radiofrequency and microwave ablation electrodes used for the ablation of tumors.
This report covers the impact of COVID-19 on the oncology ablation catheters market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as AngioDynamics, Boston Scientific, Medtronic, and others. The report provides insights into trends, drivers, and limiters of the oncology ablation catheters market, as well as highlights potential opportunities.
The COVID-19 pandemic had a minimal impact on the global oncology ablation catheters market. The pandemic has affected elective surgical procedures tremendously as these procedures have been canceled or postponed so that healthcare resources are conserved for the treatment of COVID-19 and other critical surgeries, including surgical procedures for the treatment of cancers.
While there are many therapeutic options for cancer, catheter ablation is emerging as a favorable means for treatining patients via a minimally invasive procedure. Catheter ablation utilizes two common methods, radiofrequency or microwave ablation and cryoablation.
Medtronic and AngioDynamics together account for approximately 70% share of the global oncology ablation catheters market. The Starburst product platform from AngioDynamics and UltraCool & Thermosphere from Medtronic are the market-leading products for catheter ablation for the treatment of cancers.